Back to top
more

Insulet (PODD)

(Delayed Data from NSDQ)

$166.26 USD

166.26
688,849

-6.45 (-3.73%)

Updated Apr 17, 2024 03:59 PM ET

After-Market: $166.22 -0.04 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PODD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

1 item in cart

View Cart/Checkout

Insulet Corporation [PODD]

Reports for Purchase

Showing records 141 - 160 ( 340 total )

Company: Insulet Corporation

Industry: Medical - Products

Record: 141

04/17/2017

Daily Note

Pages: 41

1Q17 Preview: Outperforming in MedTech Year-to-Date Reflects Stable Fundamentals That Should Continue Throughout 2017

Provider: WEDBUSH SECURITIES INC.

Price: 100.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 142

03/27/2017

Daily Note

Pages: 5

Monthly Neulasta Onpro Prescription Tracker (February): Share of Onpro Slips Slightly in February

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 143

02/28/2017

Company Report

Pages: 10

Revenue strong in Q4, guidance inline with expectations - maintain HOLD, $41.50PT

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 144

02/28/2017

Company Report

Pages: 9

PODD Delivers a Solid Quarter and Issues Healthy Outlook; Reiterate OUTPERFORM and Raising PT to $50

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 145

02/27/2017

Company Report

Pages: 8

Insulin Pump Project: Historical survey of ~7,000 users

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 146

02/22/2017

Daily Note

Pages: 5

Monthly Neulasta Onpro Prescription Tracker (January): Normalizing for the Expected Semi-Annual Spike in Neulasta Scripts, Share of Onpro at Over 50%

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 147

02/03/2017

Daily Note

Pages: 4

Update on Neulasta Onpro Kit From Amgen''s EPS Call; Share of Neulasta Franchise Expected To Continue Growing

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 148

01/24/2017

Industry Report

Pages: 6

Medical Devices: Diabetes Market Implications from JNJ''s Potential Exit

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 149

01/13/2017

Industry Report

Pages: 6

CMS to Reimburse DXCM''s G5; Positive for DXCM, PODD, TNDM; Negative for MDT

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 150

12/21/2016

Daily Note

Pages: 5

Monthly Neulasta Onpro Prescription Tracker (November): Latest RX Data Continue To Point Toward 50% Share of Neulasta by Yearend; Reit. OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 151

11/23/2016

Daily Note

Pages: 5

Monthly Neulasta Onpro Prescription Tracker: October Results In Line; On Track For 50% Share of Neulasta by Yearend; Reit. OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 152

11/17/2016

Daily Note

Pages: 9

Analyst Day Highlights a Solid Foundation From Which to Drive Robust Growth; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 153

11/04/2016

Company Report

Pages: 9

Another "beat-and-raise", strength across the board - reiterate BUY, target to $41.50

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 154

11/04/2016

Company Report

Pages: 8

3Q16 Results - A Ray of Sunshine in an Otherwise Gloomy Diabetes Quarter; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 155

11/01/2016

Company Report

Pages: 7

Insulin Pump Project: Historical survey of ~6,700 users

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 156

10/27/2016

Daily Note

Pages: 5

Amgen''s Reported Onpro Kit Share In Line with Our Analysis and On Track to Capture 50% of Neulasta Franchise Exiting 2016; Maintain OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 157

10/19/2016

Daily Note

Pages: 5

Monthly Neulasta Onpro Prescription Tracker: September Resumes Onpro''s Growing Share of the Amgen''s Neulasta Franchise;Maintain OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 158

10/17/2016

Daily Note

Pages: 39

3Q16 Preview: Stable Growth Trends Through The End of 2016

Provider: WEDBUSH SECURITIES INC.

Price: 75.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 159

09/29/2016

Industry Report

Pages: 6

670G Approval Significantly Ahead of Expectations, but Launch Date is in Line; Impact to Competitors to be Minor

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 160

09/29/2016

Industry Report

Pages: 6

670G Approval Significantly Ahead of Expectations, but Launch Date is in Line; Impact to Competitors to be Minor

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party